All In Biotech

Drug Trial Radar · NCT04718896

A Study to Assess the Pharmacokinetics, Safety, and Efficacy of Two Doses of Bimekizumab in Adolescent Study Participants With Moderate to Severe Plaque Psoriasis

A Multicenter, Open-Label, Randomized Study to Assess the Pharmacokinetics, Safety, and Efficacy of Two Doses of Bimekizumab in Adolescent Study Participants With Moderate to Severe Plaque Psoriasis

Last checked: Nov 20, 2026Latest source record: Aug 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

41

Actual

Start

Apr 6, 2021

Primary completion

Mar 12, 2025

Study completion Mar 12, 2025

Sponsor

Lead sponsor
UCB Biopharma SRLUCB
Sponsor type
Industry
First posted
Jan 22, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to assess th pharmacokinetics (PK) of bimekizumab administered subcutaneously (sc) in adolescents with moderate to severe plaque psoriasis (PSO).

Conditions

  • Moderate to Severe Plaque Psoriasis

Interventions

  • bimekizumabDrug

    Study participants will receive subcutaneously administered bimekizumab (BKZ) at pre-specified time points during the study.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Plasma Concentration of Bimekizumab at Week 0Time frame: Baseline (Week 0)
  2. Plasma Concentration of Bimekizumab at Week 1Time frame: Week 1
  3. Plasma Concentration of Bimekizumab at Week 4Time frame: Week 4
  4. Plasma Concentration of Bimekizumab at Week 8Time frame: Week 8
  5. Plasma Concentration of Bimekizumab at Week 12Time frame: Week 12
  6. Plasma Concentration of Bimekizumab at Week 16Time frame: Week 16
  7. Plasma Concentration of Bimekizumab at Week 20Time frame: Week 20
  8. Plasma Concentration of Bimekizumab at Week 40Time frame: Week 40
  9. Plasma Concentration of Bimekizumab at Week 64Time frame: Week 64
  10. Plasma Concentration of Bimekizumab at Week 88Time frame: Week 88
  11. Plasma Concentration of Bimekizumab at Week 112Time frame: Week 112
  12. Plasma Concentration of Bimekizumab at Week 124Time frame: Week 124
  13. Plasma Concentration of Bimekizumab at Safety Follow up (SFU)Time frame: Week 140 (SFU)

Locations

11 sites in 4 countries. Site status is shown where the registry gives one.

  • Ps0020 50344

    Indianapolis, Indiana

  • Ps0020 50359

    Cypress, Texas

  • Ps0020 50354

    Calgary, Canada

  • Ps0020 50357

    St. John's, Canada

  • Ps0020 40645

    Frankfurt, Germany

  • Ps0020 40626

    Bialystok, Poland

  • Ps0020 40625

    Lodz, Poland

  • Ps0020 40396

    Rzeszów, Poland

  • Ps0020 40335

    Warsaw, Poland

  • Ps0020 40333

    Wroclaw, Poland

  • Ps0020 40334

    Wroclaw, Poland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.